Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on February 19, 2014. The report discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
Effective February 19, 2014, the Board of Directors appointed Michael W. George as a director. He will hold office until the 2014 annual meeting of stockholders. The filing confirms there were no arrangements or understandings regarding his appointment and no related party transactions exist between Mr. George and the company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It is a standard disclosure of a director appointment.
Key Facts for Investors to Verify
- Michael W. George's appointment as a director effective February 19, 2014.
- Mr. George's background includes over 25 years of sales and marketing experience with major pharmaceutical companies (DuPont Merck, Bristol Myers, Sandoz/Novartis) and roles as a restructuring executive.
- Mr. George currently serves as CEO of Michael George & Associates and sits on the boards of ClearPath Diagnostics, Inc. and Coastal Horizons, Inc.
- Confirmation that no related party transactions exist between the new director and Cormedix Inc.